Solid Biosciences Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Solid Biosciences Inc. (SLDB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 16.03 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-06
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 12.40K shares, a 83.42% decline year-over-year.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 3.63K shares, a 87.52% decline year-over-year.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 935.00 shares, a 87.37% decline year-over-year.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 104.82K shares, a 75.91% decline from fiscal 2024.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 435.17K shares, a 66.86% increase from fiscal 2023.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 260.80K shares, a 117.33% increase from fiscal 2022.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 120.01K shares, a 85.03% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 12.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 16.03K shares 10-Q · filed 2026-08-06 | 16.03K shares derived: sum of 3 quarters · filed 2026-08-06 | 16.97K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 3.63K shares 10-Q · filed 2026-05-12 | 3.63K shares derived: sum of 2 quarters · filed 2026-05-12 | 4.57K shares derived: sum of 3 quarters · filed 2026-05-12 | 79.34K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 935.00 shares derived: sum of 2 quarters · filed 2026-03-19 | 75.71K shares derived: sum of 3 quarters · filed 2026-03-19 | 104.82K shares 10-K · filed 2026-03-19 |
| 2025-09-30 | 935.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | 75.71K shares derived: sum of 2 quarters · filed 2025-11-03 | 104.82K shares 10-Q · filed 2025-11-03 | 111.44K shares derived: sum of 4 quarters · filed 2025-11-03 |
| 2025-06-30 | 74.78K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 103.88K shares 10-Q · filed 2025-08-12 | 110.51K shares derived: sum of 3 quarters · filed 2025-08-12 | 117.91K shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 29.11K shares 10-Q · filed 2025-05-15 | 35.73K shares derived: sum of 2 quarters · filed 2025-05-15 | 43.13K shares derived: sum of 3 quarters · filed 2025-05-15 | |
| 2024-12-31 | 6.62K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 14.03K shares derived: sum of 2 quarters · filed 2025-03-06 | 435.17K shares 10-K · filed 2025-03-06 | |
| 2024-09-30 | 7.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 428.55K shares 10-Q · filed 2024-11-06 | ||
| 2024-06-30 | 421.15K shares 10-Q · filed 2024-08-13 | |||
| 2023-12-31 | 260.80K shares 10-K · filed 2024-03-13 | |||
| 2022-12-31 | 120.01K shares 10-K · filed 2023-03-23 | |||
| 2021-12-31 | 801.86K shares 10-K · filed 2022-03-14 | |||
| 2020-12-31 | 1.01M shares 10-K · filed 2021-03-15 | |||
| 2019-12-31 | 243.12K shares 10-K · filed 2020-03-12 | |||
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | 26.60K shares derived: sum of 2 quarters · filed 2019-03-13 | 32.01K shares 10-K · filed 2019-03-13 | |
| 2018-09-30 | 26.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | 32.01K shares 10-Q · filed 2018-11-13 | ||
| 2018-06-30 | 5.41K shares 10-Q · filed 2018-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |